Chimeric Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Oct 13

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Feb 23

We Think Chimeric Therapeutics (ASX:CHM) Needs To Drive Business Growth Carefully

Oct 20

CEO

Chimeric Therapeutics has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Hopper	Founder & Executive Chairman	4.8yrs	AU$301.98k	10.49% A$ 855.0k
Phillip Hains	CFO, Joint Company Secretary & Director	4.1yrs	no data	1.14% A$ 92.9k
Rebecca McQualter	Chief Operating Officer	less than a year	AU$453.86k	no data
Jason Litten	Chief Medical Officer	2.3yrs	AU$1.16m	no data
Kelly Thornburg	VP & Head of Quality	2.8yrs	no data	no data
Nathan Jong	Joint Company Secretary	4.1yrs	no data	no data

2.8yrs

Average Tenure

63yo

Average Age

Experienced Management: CHM's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Hopper	Founder & Executive Chairman	4.8yrs	AU$301.98k	10.49% A$ 855.0k
Phillip Hains	CFO, Joint Company Secretary & Director	1.3yrs	no data	1.14% A$ 92.9k
Larry Couture	Member of Glioblastoma Expert Advisory Board	no data	no data	no data
Eric Sullivan	Non-Executive Director	1.3yrs	AU$68.78k	no data
Lesley Russell	Non-Executive Director	4.3yrs	AU$50.00k	0.19% A$ 15.7k
David Maloney	Member of Cellular Immunotherapy Scientific Advisory Board	3.2yrs	no data	no data
Nader Sanai	Member of Glioblastoma Expert Advisory Board	no data	no data	no data
Yvonne Chen	Member of Glioblastoma Expert Advisory Board	3.8yrs	no data	no data
Christine Brown	Chairman of Glioblastoma Expert Advisory Board	no data	no data	1.34% A$ 109.5k
Yi Lin	Member of Cellular Immunotherapy Scientific Advisory Board	3.3yrs	no data	no data
Eric Smith	Member of Cellular Immunotherapy Scientific Advisory Board	3.2yrs	no data	no data
Michael Bishop	Member of Cellular Immunotherapy Scientific Advisory Board	3.2yrs	no data	no data

3.2yrs

Average Tenure

65yo

Average Age

Experienced Board: CHM's board of directors are considered experienced (3.2 years average tenure).

Chimeric Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023

Chimeric Therapeutics Limited Announces Board Changes

Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director

Chimeric Therapeutics Limited Announces Board Changes

No independent directors

Recent updates

Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024

New major risk - Share price stability

New major risk - Market cap size

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.

New major risk - Shareholder dilution

Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101

New minor risk - Share price stability

Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023

Price target decreased by 14% to AU$0.60

New minor risk - Financial data availability

Chimeric Therapeutics Limited Announces Board Changes

Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director

Chimeric Therapeutics Limited Announces Board Changes

Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical Trial

Chimeric Therapeutics Limited Announces Successful Completion of 28-Day Follow Up Period for 3rd Patient Cohort in Brain Cancer Phase 1 Trial

Chimeric Therapeutics Announces First Patient Dosed in CHM 0201 Vactosertib Trial

Chimeric Therapeutics Limited Completes Dosing in Third Cohort of CHM 1101 (CLTX CAR T) Trial

Price target decreased to AU$0.71

No independent directors

Chimeric Therapeutics Limited, Annual General Meeting, Nov 15, 2022

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Chimeric Therapeutics Limited Appoints Jason B. Litten as Chief Medical Officer

Chimeric Therapeutics Announces First Ever Phase 1B Trial of NK Cells with IL-2 & Vactosertib

Chimeric Therapeutics Announces the Completion of Manufacturing and Quality Release for CHM 1101 (CLTX CAR T) Viral Vector, a Key Milestone in its Development

No independent directors

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Chimeric Therapeutics Limited Announces Encouraging Data from 2Nd Dose Cohort in CLTX CAR T trial

Chimeric Therapeutics Limited Successful Completion of 2nd Dose Cohort in CLTX CAR T Trial

Executive Chairman recently bought AU$98k worth of stock

Chimeric Therapeutics Limited Highlights Key Additional Data Released with the Final Presentation of Two CLTX Car T Abstracts At the Society for Neuro-Oncology 26th Annual Scientific Meeting

We Think Chimeric Therapeutics (ASX:CHM) Needs To Drive Business Growth Carefully

Non-Executive Director recently bought AU$166k worth of stock

Chimeric Therapeutics Announces Initiation of Second Dose Cohort

Chimeric Therapeutics Limited Announces Successful Completion of Dosing in First Patient Cohort

Chimeric Therapeutics Appoints Cindy Elkins as Non-Executive Director

Chimeric Therapeutics Limited Appoints Dr. Yvonne Chen to Scientific Advisory Board

Chimeric Therapeutics Limited Appoints Paul Hopper as Director

Chimeric Therapeutics Limited has completed an IPO in the amount of AUD 35 million.

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age